CORRECTION OF COGNITIVE IMPAIRMENTS IN CHRONIC CEREBRAL ISCHEMIA IN OUTPATIENT SETTINGS
Keywords:
chronic cerebral ischemia, cognitive impairment, herbal medicinal collection NeuroAid II.Abstract
To study the efficacy and safety of therapy with the herbal tea NeuroAid II in patients with chronic cerebral ischemia (CCI) in outpatient settings. Sixty-five patients aged 46-74 years (mean age 60.1±3.2 years) were examined. In all patients, the diagnosis of CCI was confirmed by clinical and neuroimaging methods. Patients of the 1st group (n=37) received basic therapy and the herbal medicinal collection NeuroAid II, the 2nd group (n=28) — only basic therapy. During therapy, patients of the 1st group showed statistically significant improvement in cognitive functions, a decrease in the severity of symptoms of depression and anxiety, and manifestations of asthenia. The treatment was characterized by good tolerability, the absence of adverse events and cases of drug interactions. Therapy with the herbal medicinal collection NeuroAid II in patients with chronic cerebral ischemia in outpatient settings provides relief of the main clinical manifestations of CCI, is characterized by good tolerability and safety.
References
Adambaev Z.I., Khalikov S.V. Rehabilitation of ischemic stroke in the early recovery period with herbal medicinal mixture / Collection of materials from the Congress with international participation XXVI “Davidenkov Readings” St. Petersburg, 2024, September 19-20. P.9-10.
Gogoleva A.G., Zakharov V.V. Issues of etiology, manifestations and therapy of chronic cerebrovascular diseases. Neurology, neuropsychiatry, psychosomatics. 2020; 12(5): 84–91.
Zhuravleva M.V., Vasyukova N.S., Arkhipov V.V. and others. Results of clinical studies of the effectiveness and safety of the use of ethylmethylhydroxypyridine succinate drugs in patients with chronic cerebral ischemia. Journal of Neurology and Psychiatry named after. S.S. Korsakov. 2022;122(11): 29-39.
Zakharov V.V., Sleptsova K.B., Martynova O.O. Chronic cerebral ischemia: a view from the 21st century. RMJ. 2021;5:45-49.
Kadykov A.S., Manvelov L.S. Tests and scales in neurology: a guide for doctors. M.: MEDpress-inform, 2015. 224 p.
Mirdzhuraev E.M., Samiev A.S., Zhiyanov Z.B. Analysis of the effectiveness of treatment of patients with cognitive changes in diseases of chronic cerebrovascular accidents // Journal of Neurological and Neurosurgical Research, 2024; 41:36-38.
Mirshavkatovich M. E., Sayitovich S. A., Ulashovich U. S. Bosh miyada surunkli kon aylanishi kasallaridagi cognitive uzgarishli bemorlarni davolashni davolashning samaradorligi takhlili. //JOURNAL OF BIOMEDICINE AND PRACTICE. – 2024. – T. 9. – No. 2.
Fedin A.I., Zakharov V.V., Tanashyan M.M. and others. Results of an international multicenter randomized, double-blind, placebo-controlled study assessing the effectiveness and safety of sequential therapy of patients with chronic cerebral ischemia with Mexidol and Mexidol Forte 250 (MEMO study). Journal of Neurology and Psychiatry named after. S.S. Korsakov. 2021;121(11):7-16
Fedin A.I., Saverskaya E.N., Badalyan K.R. Multimodal therapeutic strategies in the treatment of cerebrovascular disease. Journal of Neurology and Psychiatry named after. S.S. Korsakov. 2021; 121(12): 1–7.
Khakimova, S., Khamdamova, B., & Akhmedova, Ch. (2024). The role of liquorodynamic disorders in patients with chronic cerebral ischemia (CE). Preventive Medicine and Health, 3(5), 40-45.
Sattarova, S. Z., Mamurova, I. N., Samiev, A. S., & Khakimova, S. Z. (2019). The relationship of anosognosia with cognitive disorders, levels of anxiety and depression in the acute period of ischemic stroke. Academy, (10(49)), 61-64.
Christopher L.H. Chen BM, Qingshu Lu, Rajesh Babu Moorakonda, Nagaendran Kandiah, Boon Yeow Tan, Steven Gayoles Villaraza, Jemelle Cano, Narayanaswamy Venketasubramanian. Alzheimer’s Disease Therapy With Nеuroaid [ATHENE]): randomized, double-blind, delayed-treatment study // JAMDA, 2022; 23:379-386.
Livingston G., Huntley J., Sommerlad A. et al. Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. Lancet. 2020; 396(10248): 413–46. https://dx.doi.org/10.1016/S0140-6736(20)30367-6.
Alimjanovich , R. Z., Maxammatkulovich , R. N., & Khikmatovich , K. K. (2022). Age Features of the Prevalence of Prostate Cancer in Uzbekistan. Central Asian Journal of Medical and Natural Science, 3(5), 154-157. Retrieved from
Rizaev Jasur , Rakhimov Nodir , Kodyrov Khamidullo , Shakhanova Shakhnoza . Study of prostate cancer death by regions of the republic of Uzbekistan.Journal of Biomedicine and Practice. 2022, vol . 7, issue 5, pp.202-210
Shavkatovna S. S., Makhammatkulovich R. N., Ugli M. S. T. ASPECTS OF SARCOPENIA SYNDROME IN ONCOLOGICAL PRACTICE: DIAGNOSIS AND TREATMENT //The American Journal of Medical Sciences and Pharmaceutical Research. – 2024. – Т. 6. – №. 02. – С. 16-25
Suwanwela NC, Chen CLH, Lee CF, Young SH, Tay SS, Umapathi T, Lao AY, Gan HH, Baroque Ii AC, Navarro JC, Chang HM, Advincula JM, Muengtaweepongsa S, Chan BPL, Chua CL, Wijekoon N, de Silva HA, Hiyadan JHB, Wong KSL, Poungvarin N, Eow GB, Venketasubramanian N; CHIMES-E Study Investigators. Effect of Combined Treatment with MLC601 (NeuroAiDTM) and Rehabilitation on Post-Stroke Recovery: The CHIMES and CHIMES-E Studies. Cerebrovasc Dis. 2018;46(1-2):82-88. doi: 10.1159/000492625. Epub 2018 Sep 5. PMID: 30184553; PMCID: PMC6214602.
